---
title: "CHAIN BRIDGE I | 10-Q: FY2025 Q2 EPS: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253096083.md"
datetime: "2025-08-14T20:09:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253096083.md)
  - [en](https://longbridge.com/en/news/253096083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253096083.md)
generator: "portal-rs"
---

# CHAIN BRIDGE I | 10-Q: FY2025 Q2 EPS: USD 0

EPS: As of FY2025 Q2, the actual value is USD 0.

EBIT: As of FY2025 Q2, the actual value is USD -305.28 K.

### Segment Revenue

-   The company did not generate any operating revenues during the period as it is a blank check company focused on effecting a business combination.

### Operational Metrics

-   **Net Income (Loss)**: For the three months ended June 30, 2025, net income was approximately $5,800, compared to a net loss of approximately $448,000 for the same period in 2024.
-   **General and Administrative Expenses**: For the three months ended June 30, 2025, general and administrative expenses were approximately $275,000, compared to $563,000 for the same period in 2024.
-   **Change in Fair Value of Derivative Liabilities**: Gain of approximately $242,000 for the three months ended June 30, 2025.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was approximately - $273,548.
-   **Net Cash Provided by (Used in) Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was approximately $174,150.

### Unique Metrics

-   **Investment Income on Trust Account**: For the three months ended June 30, 2025, investment income was approximately $56,000.

### Future Outlook and Strategy

-   **Core Business Focus**: The company has until November 15, 2025, to consummate an initial Business Combination. If not completed by this date, the company must cease operations, redeem public shares, and liquidate.
-   **Non-Core Business**: The company is focused on completing a business combination with Phytanix Bio, which is expected to close within the SEC’s prescribed timeline.
-   **Priority**: The company is committed to ensuring compliance with the Investment Company Act and the updated SEC guidance, aiming to mitigate risks associated with the potential application of the Investment Company Act.

### Related Stocks

- [CBRRF.US](https://longbridge.com/en/quote/CBRRF.US.md)

## Related News & Research

- [Why is your gold waiting on a speech?](https://longbridge.com/en/news/296733808.md)
- [North Sea Crude-WTI weakens on lower offer](https://longbridge.com/en/news/296813963.md)
- [Nvidia Earnings: Wall Street Expects Growth to Slow in Q2 — Dan Niles Says Hyperscalers Are Spending Like Never Before](https://longbridge.com/en/news/296822352.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)
- [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**